USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Zhejiang Huakang Pharmaceutical Co., Ltd.

USPTO PatentsView assignee record - 13 granted patents across 23 technology areas, active 2023–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C13K (SACCHARIDES OBTAINED FROM NATURAL SOURCES OR BY HYDROLYSIS OF NATURALLY OCCURRING DISACCHARIDES, OLIGOSACCHARIDES OR POLYSACCHARIDES).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

Total patents granted

CPC technology areas

7.8

Avg claims per patent

5-year filing velocity

The verdict

Zhejiang holds 13 US patents across 23 technology areas, rank #22,081 of 50,000 tracked assignees.

#22,081
of 50,000 US assignees by volume: Top 12%
by Innovation Score (50.7/100): 7.8
avg claims per patent

Portfolio overview

Zhejiang Huakang Pharmaceutical Co., Ltd. has been granted 13 US utility patents between 2023 and 2025, placing Zhejiang Huakang Pharmaceutical Co., Ltd. at rank #22,081 across all assignees tracked by PlainPatent. This portfolio spans 23 distinct Cooperative Patent Classification (CPC) subclasses, averaging 7.8 claims per patent with primary concentration in C13K (SACCHARIDES OBTAINED FROM NATURAL SOURCES OR BY HYDROLYSIS OF NATURALLY OCCURRING DISACCHARIDES, OLIGOSACCHARIDES OR POLYSACCHARIDES). As a Foreign Corporation, Zhejiang Huakang Pharmaceutical Co., Ltd. is one of the more focused assignees in the PatentsView dataset. By volume, Zhejiang sits between Zynerba Pharmaceuticals, Inc. (13 patents, rank #22,077) and Zighra, Inc. (13 patents, rank #22,085) - the closest US assignees by grant volume. The composite Innovation Score of 50.7/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Historical data spans 2023 through 2025, with 13 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Zhejiang Huakang Pharmaceutical Co., Ltd.'s 7.8 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while a multi-domain presence across 23 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Zhejiang Huakang Pharmaceutical Co., Ltd. against peers pursuing similar technology classes.

Zynerba Pharmaceu…

13
ZYP Coatings

13
Zambon S P A

13
Zetta

13
Zhejiang Kaiying…

13
Zhik Pty

13
Zhuhai Beihai Bio…

13
Zighra

13
Zhejiang Huakang… ◀

13

What this shows Zhejiang holds 13 patents at rank #22,081, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Zhejiang

By rank, the assignees closest to #22,081 in granted patent volume.

Leaders in C13K (Saccharides Obtained FROM Natural Sources OR BY Hydrolysi…)

Other assignees with the most granted patents in Zhejiang's primary technology class.

Zhejiang's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

51 Top 12% higher than 88% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2023–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.

View data table

Zhejiang Huakang Pharmaceutical Co., Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2023	2	15.4%
2024	5	38.5%
2025	6	46.2%

Which technologies does Zhejiang Huakang Pharmaceutical Co., Ltd. patent most?

C13K - SACCHARIDES OBTAINED FROM NATURAL SOURCES OR BY HYDROLYSIS OF NATURALLY OCCURRING DISACCHARIDES, OLIGOSACCHARIDES OR POLYSACCHARIDES 5

Y02P - CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS 4

B01D - SEPARATION 4

A23L - FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF 4

C07C - ACYCLIC OR CARBOCYCLIC COMPOUNDS 4

D21C - PRODUCTION OF CELLULOSE BY REMOVING NON-CELLULOSE SUBSTANCES FROM CELLULOSE-CONTAINING MATERIALS; REGENERATION OF PULPING LIQUORS; APPARATUS THEREFOR 2

C12P - FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 2

B01J - CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS 2

C07H - SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 2

D21H - PULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G; PAPER NOT OTHERWISE PROVIDED FOR 1

C08B - POLYSACCHARIDES; DERIVATIVES THEREOF 1

C08H - DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS 1

C08L - COMPOSITIONS OF MACROMOLECULAR COMPOUNDS 1

G06F - ELECTRIC DIGITAL DATA PROCESSING 1

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 1

Top 15 of 23 technology areas

Patent Moat Analysis

Portfolio Volume Light

Tech Breadth Multi-domain

Claim Depth Simple

Where it ranks

Overall rank by patents

#22,081

Across all tracked assignees

Innovation Score

50.7 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Zhejiang Huakang Pharmaceutical Co., Ltd. hold?

Zhejiang Huakang Pharmaceutical Co., Ltd. holds 13 US granted patents filed between 2023 and 2025, spanning 23 technology areas.

What is Zhejiang Huakang Pharmaceutical Co., Ltd.'s Innovation Score?

Zhejiang Huakang Pharmaceutical Co., Ltd. has an Innovation Score of 50.7 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Zhejiang Huakang Pharmaceutical Co., Ltd. focus on?

Zhejiang Huakang Pharmaceutical Co., Ltd.'s top technology area is C13K (SACCHARIDES OBTAINED FROM NATURAL SOURCES OR BY HYDROLYSIS OF NATURALLY OCCURRING DISACCHARIDES, OLIGOSACCHARIDES OR POLYSACCHARIDES) with 5 patents. The company has filed patents in 23 CPC subclasses total.

Is Zhejiang Huakang Pharmaceutical Co., Ltd.'s patent filing rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Zhejiang Huakang Pharmaceutical Co., Ltd..

What does claim depth mean for Zhejiang Huakang Pharmaceutical Co., Ltd.'s patents?

Zhejiang Huakang Pharmaceutical Co., Ltd.'s patents average 7.8 claims each. This is relatively simple claim structure, typical for focused inventions.

How is the Zhejiang Huakang Pharmaceutical Co., Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Zhejiang's 13 grants land it in the top 12% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Zhejiang ranks #22,081 of 50,000. Top 50 holders
Most of this portfolio concentrates in C13K - see who else leads that technology area. C13K leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.